Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway

RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells

(2016) Ulrike Höckendorf et al.   CANCER CELL

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles

(2016) X. Jiang et al.   CANCER RESEARCH

Cancer therapy in the necroptosis era

(2016) Z Su et al.   CELL DEATH AND DIFFERENTIATION

Necroptosis and its role in inflammation

(2015) Manolis Pasparakis et al.   NATURE

The diverse role of RIP kinases in necroptosis and inflammation

(2015) John Silke et al.   NATURE IMMUNOLOGY

FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells

(2015) Dewen You et al.   Cell Reports

Esthesioneuroblastoma

(2014) Kelly K. Gallagher et al.   ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY

RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis

(2014) James A. Rickard et al.   CELL

RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3

(2014) Christopher P. Dillon et al.   CELL

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML

(2014) Andrew Volk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities

(2014) S Fulda   LEUKEMIA

RIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity

(2014) Pratyusha Mandal et al.   MOLECULAR CELL

RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis

(2014) Nozomi Takahashi et al.   NATURE

RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis

(2014) Marius Dannappel et al.   NATURE

Necroptosis

(2014) Andreas Linkermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small-molecule SMAC mimetics as new cancer therapeutics

(2014) Longchuan Bai et al.   PHARMACOLOGY & THERAPEUTICS

Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages

(2014) S. McComb et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis

(2014) Justine E. Roderick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activity of Protein Kinase RIPK3 Determines Whether Cells Die by Necroptosis or Apoptosis

(2014) K. Newton et al.   SCIENCE

Necroptosis in health and diseases

(2014) Wen Zhou et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

The mechanism of necroptosis in normal and cancer cells

(2013) Simone Fulda   CANCER BIOLOGY & THERAPY

A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition

(2013) Daniel J. Goff et al.   Cell Stem Cell

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell

Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL

(2013) William J. Kaiser et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia

(2013) Jun Zhang et al.   Molecular Oncology

Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis

(2013) L Steinhart et al.   Cell Death & Disease

Histologic Tumor Necrosis Is an Independent Prognostic Indicator for Clear Cell and Papillary Renal Cell Carcinoma

(2012) Martin Pichler et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase

(2012) A Degterev et al.   CELL DEATH AND DIFFERENTIATION

Ubiquitination in signaling to and activation of IKK

(2012) Zhijian J. Chen   IMMUNOLOGICAL REVIEWS

How to manage acute promyelocytic leukemia

(2012) J-Q Mi et al.   LEUKEMIA

Targeting IAP proteins for therapeutic intervention in cancer

(2012) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models

(2012) N Takahashi et al.   Cell Death & Disease

TNF- /Fas-RIP-1-induced cell death signaling separates murine hematopoietic stem cells/progenitors into 2 distinct populations

(2011) Y. Xiao et al.   BLOOD

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

(2011) S.-J. Chen et al.   BLOOD

Many stimuli pull the necrotic trigger, an overview

(2011) N Vanlangenakker et al.   CELL DEATH AND DIFFERENTIATION

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Curing APL through PML/RARA degradation by As2O3

(2011) Valerie Lallemand-Breitenbach et al.   TRENDS IN MOLECULAR MEDICINE

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML

(2010) Bing Z. Carter et al.   APOPTOSIS

Non-canonical NF-κB signaling pathway

(2010) Shao-Cong Sun   CELL RESEARCH

Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis

(2010) Federica Servida et al.   INVESTIGATIONAL NEW DRUGS

Smac mimetics: implications for enhancement of targeted therapies in leukemia

(2010) E Weisberg et al.   LEUKEMIA

Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010

(2009) D. Pulte et al.   ANNALS OF ONCOLOGY

The Role of Ubiquitin in NF-κB Regulatory Pathways

(2009) Brian Skaug et al.   Annual Review of Biochemistry

Smac mimetics as new cancer therapeutics

(2009) Derrick J. Chen et al.   ANTI-CANCER DRUGS

Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation

(2009) YoungSik Cho et al.   CELL

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

(2009) Aaron D. Schimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

(2009) Emma Dean et al.   JOURNAL OF CLINICAL ONCOLOGY

Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

(2009) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apoptosis in leukemia: From molecular pathways to targeted therapies

(2008) Aaron D. Schimmer   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE